AKERO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.74 USD | +4.28% |
|
-4.91% | -15.46% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 633.9 | 895.8 | 737.9 | 2,563 | 1,301 | 1,365 | - | - |
| Enterprise Value (EV) 1 | 633.9 | 627.4 | 549.6 | 2,221 | 775.8 | 977.5 | 1,083 | 1,023 |
| P/E ratio | -7.65 x | -10.2 x | -7.32 x | -19.1 x | -8.08 x | -5.01 x | -4.4 x | -4.74 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | 93.7 x |
| EV / Revenue | - | - | - | - | - | - | - | 70.3 x |
| EV / EBITDA | -13.9 x | -8.47 x | -5.45 x | -19.3 x | -4.49 x | -3.93 x | -3.85 x | -3.47 x |
| EV / FCF | -17.8 x | -8.84 x | -6.9 x | -24 x | -5.34 x | -6.39 x | -5.18 x | -4.78 x |
| FCF Yield | -5.62% | -11.3% | -14.5% | -4.17% | -18.7% | -15.7% | -19.3% | -20.9% |
| Price to Book | 2.6 x | 3.46 x | 4.36 x | 6.54 x | 2.29 x | 3.12 x | 4.98 x | 4.85 x |
| Nbr of stocks (in thousands) | 28,559 | 34,722 | 34,888 | 46,763 | 55,710 | 69,151 | - | - |
| Reference price 2 | 22.20 | 25.80 | 21.15 | 54.80 | 23.35 | 19.74 | 19.74 | 19.74 |
| Announcement Date | 3/16/20 | 3/16/21 | 2/25/22 | 3/17/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 14.56 |
| EBITDA 1 | -45.65 | -74.12 | -100.8 | -115.1 | -172.8 | -248.7 | -281.1 | -295 |
| EBIT 1 | -45.65 | -80.15 | -100.9 | -115.2 | -172.9 | -239.8 | -275.2 | -278.3 |
| Operating Margin | - | - | - | - | - | - | - | -1,911.11% |
| Earnings before Tax (EBT) 1 | -43.76 | -79.21 | -100.8 | -112 | -151.8 | -229.9 | -266.5 | -257.4 |
| Net income 1 | -43.76 | -79.21 | -100.8 | -112 | -151.8 | -232.9 | -274 | -283.6 |
| Net margin | - | - | - | - | - | - | - | -1,947.27% |
| EPS 2 | -2.900 | -2.520 | -2.890 | -2.870 | -2.890 | -3.940 | -4.490 | -4.163 |
| Free Cash Flow 1 | -35.63 | -70.95 | -79.68 | -92.52 | -145.4 | -153 | -209 | -214.3 |
| FCF margin | - | - | - | - | - | - | - | -1,471.87% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/16/21 | 2/25/22 | 3/17/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -21.73 | -32.43 | -26.04 | -27.58 | -36.08 | -25.41 | -28.74 | -35.62 | -46.61 | -61.87 | -66 | -71 | -76 | -81 | - |
| EBIT 1 | -24.35 | -32.44 | -26.05 | -27.59 | -36.09 | -25.42 | -28.75 | -35.63 | -46.62 | -61.87 | -57.87 | -59.42 | -61.93 | -68.06 | -67.6 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -24.33 | -32.42 | -26.03 | -27.4 | -35.54 | -23.06 | -25.83 | -31.08 | -39.66 | -55.19 | -54.55 | -54.62 | -57.35 | -66.12 | - |
| Net income 1 | -24.33 | -32.42 | -26.03 | -27.4 | -35.54 | -23.06 | -25.83 | -31.08 | -39.66 | -55.19 | -54.56 | -56.17 | -58.75 | -64.95 | -68.85 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.7000 | -0.9300 | -0.7400 | -0.7700 | -0.9200 | -0.4900 | -0.5500 | -0.6000 | -0.7100 | -0.9900 | -0.9525 | -0.9717 | -1.012 | -1.120 | -1.207 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 2/25/22 | 5/6/22 | 8/5/22 | 11/4/22 | 3/17/23 | 5/15/23 | 8/11/23 | 11/13/23 | 2/29/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 268 | 188 | 342 | 525 | 388 | 282 | 342 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -35.6 | -71 | -79.7 | -92.5 | -145 | -153 | -209 | -214 |
| ROE (net income / shareholders' equity) | -111% | -40.9% | -47.1% | -45.2% | -35.2% | -51.3% | -94.1% | -115% |
| ROA (Net income/ Total Assets) | -40.7% | -38.5% | -43% | -40.6% | -32.4% | -51.7% | -65.8% | -77.7% |
| Assets 1 | 107.6 | 205.7 | 234.4 | 276.1 | 468.4 | 450.4 | 416.5 | 364.9 |
| Book Value Per Share 2 | 8.540 | 7.450 | 4.860 | 8.380 | 10.20 | 6.320 | 3.960 | 4.070 |
| Cash Flow per Share 2 | - | - | -2.290 | - | - | -2.480 | -3.250 | - |
| Capex 1 | - | - | - | - | - | 3.86 | 5.71 | 7.14 |
| Capex / Sales | - | - | - | - | - | - | - | 49.05% |
| Announcement Date | 3/16/20 | 3/16/21 | 2/25/22 | 3/17/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
19.74
USD
Average target price
47.5
USD
Spread / Average Target
+140.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.46% | 1.37B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- AKRO Stock
- Financials Akero Therapeutics, Inc.
